News

2022

• 19.12.2022: A*STAR Research Attachment Programme" (ARAP), an international exchange program for PhD students with the renowned research organization Agency for Science, Technology and Research (A*STAR) in Singapore, was successfully initiated.

• 11.10.2022: Our new study just published in Molecular Cancer unveils a hitherto unknown  BRAF kinase fusion in a patient with Hashimoto thyroiditis and several druggable targets in papillary Thyroid Cancers (PTCs). This is accomplished by integrative multiomics analysis of a cohort of  PTC patients from our cancer center who scored negative for RAS and BRAF. This DKH, FZI and  CRC1292 (TP05)  funded study exemplifies the translational biomedicine research happening at UMC-Mainz. We thank the patients who volunteered for this study and congratulations to all the authors !!

• 18.03.2022: Recent publication in "Science Advances" describes that ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers!

2021

• 19.07.2021: Interview with Prof. Krishnaraj Rajalingam, "the city's newest biotechnology founder"!

• 17.05.2021: Successful foundation of KHR Biotech, a spin-off aiming to develop innovative therapeutics for cancer treatment. KHR Biotech is a joint venture project with the company Indivumed GmbH!

• 24.02.2021: New Review published, describing the "Druggable genome and precision medicine in cancer: current challenges"

2020

• 17.10.2020: Recent publication in "Cancer Gene Therapy"! A new study from CBU identified a critical role for the understudied , atypical MAPK ERK3 in controlling KRAS-mediated Non small cell lung carcinomas. KRAS is one of the most frequently mutated oncogenes and mechanisms driving tumourigenesis mediated by this oncogene have been intensively studied. Our new work demonstrated that the kinase activity of ERK3 is required for KRAS-mediated NSCLCs thus prompting development of ERK3 specific inhibitors. To read the full story click here
  

• 25.06.20: Recent publication in "Nature Communications" describes the identification of new druggable targets and of a novel TFG-RET gene fusion in papillary thyroid carcinomas!

• 17.01.20: Memorandum of Understanding signed with IMCB of the Agency for Science (A*STAR) of Singapur: Closer Cooperation in research and in the training of young scientists is initiated.

2019

• 05.04.19: We are Leica Reference Center. For the German press release please click here

2018

• 11.09.2018: Interview with Krishnaraj Rajalingam about his career from the Emmy-Noether-program of the DFG to the Heisenberg professorship

• 20.08.2018: Publication in EMBO Journal describes a new therapeutic approach against multiple sclerosis

• 04.05.2018: Else Kröner-Fresenius-Foundation supports research project of Prof. Dr. Rajalingam to explore new therapeutic approaches against lung cancer

• 23.04.2018: Deutsche Krebshilfe is now funding a innovative science project to find new therapeutic approaches against papillary thyroid carcinoma

2016

• 30.05.2016 Gutenberg Research College welcomes new member and bestows the Gutenberg Research Award 2016

• 12.05.2016 Vishva Dixit receives the Gutenberg Research Award 2016 for his work on apoptotic signaling and visits Prof. Krishnaraj Rajalingam´s Molecular Signaling Unit

• 03.05.2016 Gutenberg Research Award 2016 goes to cell death researcher Vishva Dixit

2015

• 05.05.2015: Gutenberg Research College welcomes new members and the Gutenberg Research Award 2015 is granted

2014

• 08.12.2014: New Molecular Signaling Unit of the Research Center for Immunotherapy (FZI) initiated by the Heisenberg professor Krishnaraj Rajalingam

• 30.10.2014: GFK fellow Krishnaraj Rajalingam joins the team of the Research Center for Immunotherapy at Johannes Gutenberg University Mainz

• 21.07.2014: Molecular biologist Krishnaraj Rajalingam receives Heisenberg professorship at University Medical Center Mainz